{
    "clinical_study": {
        "@rank": "21854", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: Apixaban (Reference - whole tablet)", 
                "arm_group_type": "Experimental", 
                "description": "Apixaban whole tablet by mouth once on specified days"
            }, 
            {
                "arm_group_label": "Arm B: Apixaban (crushed & suspended in water)", 
                "arm_group_type": "Experimental", 
                "description": "Apixaban tablets (crushed and suspended in water) by mouth once on specified days"
            }, 
            {
                "arm_group_label": "Arm C: Apixaban (crushed and mixed with applesauce)", 
                "arm_group_type": "Experimental", 
                "description": "Apixaban tablets (crushed and mixed with applesauce) by mouth once on specified days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if the bioavailability of Apixaban crushed tablets\n      suspended in water or mixed with applesauce is similar to the bioavailability of Apixaban\n      whole tablets administered orally."
        }, 
        "brief_title": "Bioavailability of Apixaban Crushed Tablet", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Thrombosis", 
        "condition_browse": {
            "mesh_term": "Thrombosis"
        }, 
        "detailed_description": {
            "textblock": "Primary Purpose: Other: This study will investigate the bioavailability of Apixaban when\n      administered as crushed tablets suspended in water and as crushed tablets mixed with\n      applesauce compared to whole tablets. The results of this study may allow enhancement of the\n      Apixaban label to include alternative methods of administration of Apixaban tablet; this may\n      be of benefit to patients who have difficulty swallowing"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Healthy subjects as determined by no clinically significant deviation from normal in\n             medical history, physical examination, electrocardiograms (ECGs), vital signs, and\n             clinical laboratory determinations\n\n          -  Women of childbearing potential allowed.  Must be following highly effective methods\n             of contraception\n\n        Exclusion Criteria:\n\n          -  Any significant acute or chronic medical illness\n\n          -  History of significant head injury within the last 2 years, including subjects with\n             base of skull fractures\n\n          -  Any major surgery within 4 weeks of study drug administration or anticipated within 2\n             weeks after completion of the study\n\n          -  Any gastrointestinal (GI) surgery or GI disease that could impact absorption of study\n             drug\n\n          -  History of Gilbert's Syndrome\n\n          -  Inability to tolerate oral medication\n\n          -  Inability to be venipunctured and/or tolerate venous access\n\n          -  Use of tobacco- or nicotine-containing products (including, but not limited to,\n             cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or\n             nicotine gum) within 6 months prior to study drug administration\n\n          -  Any of the following laboratory results outside of the ranges specified below prior\n             to study drug administration, confirmed by repeat:\n\n               -  Platelet count <150,000 cells/\u00b5L\n\n               -  Activated partial thromboplastin time (aPTT) >upper limit of normal (ULN)\n\n               -  International normalized ratio (INR) >ULN\n\n               -  Alanine aminotransferase (ALT) >ULN\n\n               -  Aspartate aminotransferase (AST) >ULN\n\n               -  Total bilirubin >ULN\n\n               -  Serum creatinine \u22651.5 mg/dL\n\n               -  Hemoglobin <lower limit of normal (LLN)\n\n               -  Hematocrit <LLN"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101112", 
            "org_study_id": "CV185-292"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm A: Apixaban (Reference - whole tablet)", 
                "Arm B: Apixaban (crushed & suspended in water)", 
                "Arm C: Apixaban (crushed and mixed with applesauce)"
            ], 
            "intervention_name": "Apixaban", 
            "intervention_type": "Drug", 
            "other_name": "Eliquis\u00ae"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 28, 2014", 
        "number_of_arms": "3", 
        "official_title": "Relative Bioavailability of Crushed Apixaban Tablets Administered With Water or Apple Sauce Compared With Intact Tablet in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed plasma concentration (Cmax) of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose"
            }, 
            {
                "measure": "Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose"
            }, 
            {
                "measure": "Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101112"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AE = Adverse Event\nSAE = Serious Adverse Event", 
                "measure": "Safety and tolerability of Apixaban measured by incidence of AEs, SAEs, and AEs leading to discontinuation; and results of vital signs, ECGs, physical examinations, and clinical laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1-12 inclusive"
            }, 
            {
                "measure": "Cmax of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose"
            }, 
            {
                "measure": "AUC(INF) of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose"
            }, 
            {
                "measure": "AUC(0-T) of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose"
            }, 
            {
                "measure": "Time of maximum observed plasma concentration (Tmax) of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose"
            }, 
            {
                "measure": "Terminal plasma half-life (T-HALF) of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose"
            }, 
            {
                "measure": "Relative bioavailability (Frel) of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}